Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 4968-4978

  Moura, Pedro A ^a   Dame, John B ^b   Fidock, David A ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; CALPASTATIN; CARBANILAMIDE DERIVATIVE; CHLOROQUINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DEETHYLCHLOROQUINE; GB III 24; GB III 28; GB III 32; HEMOGLOBIN; LEUPEPTIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; N ACETYLLEUCINYLLEUCINYLNORLEUCINE; PEPSTATIN; PLASMEPSIN I; PLASMEPSIN II; PLASMEPSIN III; PLASMEPSIN IV; PLASMEPSIN X; RO 40 4388; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ASSAY; ENZYME INHIBITION; ERYTHROCYTE LIFESPAN; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; KNOCKOUT GENE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; PROTEIN TARGETING; STRAIN DIFFERENCE;

ANIMALS; ANTIMALARIALS; ASPARTIC ACID ENDOPEPTIDASES; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HEMOGLOBINS; HYDROLYSIS; LEUPEPTINS; MALARIA, FALCIPARUM; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROTEASE INHIBITORS;

EID: 71249149462     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00882-09     Document Type: Article

References (60)

1. Andrews, K. T., D. P. Fairlie, P. K. Madala, J. Ray, D. M. Wyatt, P. M. Hilton, L. A. Melville, L. Beattie, D. L. Gardiner, R. C. Reid, M. J. Stoermer, T. Skinner-Adams, C. Berry, and J. S. McCarthy. 2006. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50:639-648.
2. Bailly, E., R. Jambou, J. Savel, and G. Jaureguiberry. 1992. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor). J. Protozool. 39:593-599.
3. Banerjee, R., S. E. Francis, and D. E. Goldberg. 2003. Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in Plasmodium falciparum. Mol. Biochem. Parasitol. 129:157-165. (Pubitemid 36794568)
4. Banerjee, R., and D. E. Goldberg. 2001. The Plasmodium food vacuole, p. 43-63. In P. J. Rosenthal (ed.), Antimalarial chemotherapy. Humana Press, Totowa, NJ.
5. Banerjee, R., J. Liu, W. Beatty, L. Pelosof, M. Klemba, and D. E. Goldberg. 2002. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA 99:990-995.
6. Bell, A. 2005. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol. Lett. 253:171-184.
7. Bhattacharya, G. 2005. Activity of amidine-containing diphenylureas against P. falciparum. Lett. Drug Des. Discov. 2:162-164.
8. Bonilla, J. A., T. D. Bonilla, C. A. Yowell, H. Fujioka, and J. B. Dame. 2007. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol. Microbiol. 65:64-75.
9. Boss, C., S. Richard-Bildstein, T. Weller, W. Fischli, S. Meyer, and C. Binkert. 2003. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr. Med. Chem. 10:883-907.
10. Bray, P. G., O. Janneh, K. J. Raynes, M. Mungthin, H. Ginsburg, and S. A. Ward. 1999. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J. Cell Biol. 145:363-376.
11. Bray, P. G., M. Mungthin, R. G. Ridley, and S. A. Ward. 1998. Access to hematin: the basis of chloroquine resistance. Mol. Pharmacol. 54:170-179.
12. Bray, P. G., and S. A. Ward. 1998. A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium falciparum. Pharmacol. Ther. 77:1-28. (Pubitemid 28059938)
13. Coombs, G. H., D. E. Goldberg, M. Klemba, C. Berry, J. Kay, and J. C. Mottram. 2001. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17:532-537.
14. Cooper, R. A., M. T. Ferdig, X. Z. Su, L. M. Ursos, J. Mu, T. Nomura, H. Fujioka, D. A. Fidock, P. D. Roepe, and T. E. Wellems. 2002. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol. 61:35-42.
15. Dahlgren, A., I. Kvarnstrom, L. Vrang, E. Hamelink, A. Hallberg, A. Rosenquist, and B. Samuelsson. 2003. New inhibitors of the malaria aspartyl proteases plasmepsin I and II. Bioorg. Med. Chem. 11:3423-3437.
16. Dame, J. B., C. A. Yowell, L. Omara-Opyene, J. M. Carlton, R. A. Cooper, and T. Li. 2003. Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Mol. Biochem. Parasitol. 130:1-12.
17. Desjardins, R. E., C. J. Canfield, J. D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
18. Drew, M. E., R. Banerjee, E. W. Uffman, S. Gilbertson, P. J. Rosenthal, and D. E. Goldberg. 2008. Plasmodium food vacuole plasmepsins are activated by falcipains. J. Biol. Chem. 283:12870-12876.
19. Ersmark, K., I. Feierberg, S. Bjelic, E. Hamelink, F. Hackett, M. J. Blackman, J. Hulten, B. Samuelsson, J. Aqvist, and A. Hallberg. 2004. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J. Med. Chem. 47:110-122.
20. Ferdig, M. T., R. A. Cooper, J. Mu, B. Deng, D. A. Joy, X. Z. Su, and T. E. Wellems. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52:985-997.
21. Fidock, D. A., T. Nomura, and T. E. Wellems. 1998. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol. Pharmacol. 54:1140-1147.
22. Fidock, D. A., and T. E. Wellems. 1997. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc. Natl. Acad. Sci. USA 94:10931-10936.
23. Fivelman, Q. L., I. S. Adagu, and D. C. Warhurst. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48:4097-4102.
24. Francis, S. E., I. Y. Gluzman, A. Oksman, A. Knickerbocker, R. Mueller, M. L. Bryant, D. R. Sherman, D. G. Russell, and D. E. Goldberg. 1994. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 13:306-317.
25. Francis, S. E., D. J. Sullivan, Jr., and D. E. Goldberg. 1997. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol. 51:97-123.
26. Gluzman, I. Y., S. E. Francis, A. Oksman, C. E. Smith, K. L. Duffin, and D. E. Goldberg. 1994. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J. Clin. Investig. 93:1602-1608.
27. Haque, T. S., A. G. Skillman, C. E. Lee, H. Habashita, I. Y. Gluzman, T. J. Ewing, D. E. Goldberg, I. D. Kuntz, and J. A. Ellman. 1999. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J. Med. Chem. 42:1428-1440.
28. He, Z., L. Qin, L. Chen, N. Peng, J. You, and X. Chen. 2008. Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrob. Agents Chemother. 52:2653-2656. (Pubitemid 351915702)
29. Hoppe, H. C., D. A. van Schalkwyk, U. I. Wiehart, S. A. Meredith, J. Egan, and B. W. Weber. 2004. Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum. Antimicrob. Agents Chemother. 48:2370-2378.
30. Ismail, M. A., R. Brun, J. D. Easterbrook, F. A. Tanious, W. D. Wilson, and D. W. Boykin. 2003. Synthesis and antiprotozoal activity of aza-analogues of furamidine. J. Med. Chem. 46:4761-4769.
31. Jiang, S., S. T. Prigge, L. Wei, Y. Gao, T. H. Hudson, L. Gerena, J. B. Dame, and D. E. Kyle. 2001. New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob. Agents Chemother. 45:2577-2584.
32. Kim, Y. M., M. H. Lee, T. G. Piao, J. W. Lee, J. H. Kim, S. Lee, K. M. Choi, J. H. Jiang, T. U. Kim, and H. Park. 2006. Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic. J. Biochem. 139:189-195.
33. Klemba, M., and D. E. Goldberg. 2005. Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum. Mol. Biochem. Parasitol. 143:183-191. (Pubitemid 41206472)
34. Lakshmanan, V., P. G. Bray, D. Verdier-Pinard, D. J. Johnson, P. Horrocks, R. A. Muhle, G. E. Alakpa, R. H. Hughes, S. A. Ward, D. J. Krogstad, A. B. S. Sidhu, and D. A. Fidock. 2005. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24:2294-2305.
35. Lee, M. C., P. A. Moura, E. A. Miller, and D. A. Fidock. 2008. Plasmodium falciparum Sec24 marks transitional ER that exports a model cargo via a diacidic motif. Mol. Microbiol. 68:1535-1546.
36. Leed, A., K. DuBay, L. M. Ursos, D. Sears, A. C. De Dios, and P. D. Roepe. 2002. Solution structures of antimalarial drug-heme complexes. Biochemistry 41:10245-10255. (Pubitemid 34856449)
37. Le Roch, K. G., Y. Zhou, P. L. Blair, M. Grainger, J. K. Moch, J. D. Haynes, P. De La Vega, A. A. Holder, S. Batalov, D. J. Carucci, and E. A. Winzeler. 2003. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 301:1503-1508.
38. Liu, J., I. Y. Gluzman, M. E. Drew, and D. E. Goldberg. 2005. The role of Plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem. 280:1432-1437.
39. Liu, J., E. S. Istvan, I. Y. Gluzman, J. Gross, and D. E. Goldberg. 2006. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. USA 103:8840-8845.
40. Mauritz, J. M., A. Esposito, H. Ginsburg, C. F. Kaminski, T. Tiffert, and V. L. Lew. 2009. The homeostasis of Plasmodium falciparum-infected red blood cells. PLoS Comput. Biol. 5:e1000339.
41. Mehlotra, R. K., H. Fujioka, P. D. Roepe, O. Janneh, L. M. Ursos, V. Jacobs-Lorena, D. T. McNamara, M. J. Bockarie, J. W. Kazura, D. E. Kyle, D. A. Fidock, and P. A. Zimmerman. 2001. Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc. Natl. Acad. Sci. USA 98:12689-12694.
42. Moon, R. P., L. Tyas, U. Certa, K. Rupp, D. Bur, C. Jacquet, H. Matile, H. Loetscher, F. Grueninger-Leitch, J. Kay, B. M. Dunn, C. Berry, and R. G. Ridley. 1997. Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur. J. Biochem. 244:552-560.
43. Mungthin, M., P. G. Bray, R. G. Ridley, and S. A. Ward. 1998. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrob. Agents Chemother. 42:2973-2977.
44. Nezami, A., and E. Freire. 2002. The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. Int. J. Parasitol. 32:1669-1676.
45. Nezami, A., T. Kimura, K. Hidaka, A. Kiso, J. Liu, Y. Kiso, D. E. Goldberg, and E. Freire. 2003. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 42:8459-8464.
46. Noteberg, D., E. Hamelink, J. Hulten, M. Wahlgren, L. Vrang, B. Samuelsson, and A. Hallberg. 2003. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. J. Med. Chem. 46:734-746.
47. Ohrt, C., G. D. Willingmyre, P. Lee, C. Knirsch, and W. Milhous. 2002. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46:2518-2524.
48. Omara-Opyene, A. L., P. A. Moura, C. R. Sulsona, J. A. Bonilla, C. A. Yowell, H. Fujioka, D. A. Fidock, and J. B. Dame. 2004. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279:54088-54096.
49. Rosenthal, P. J. 1995. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp. Parasitol. 80:272-281.
50. Rosenthal, P. J., J. H. McKerrow, M. Aikawa, H. Nagasawa, and J. H. Leech. 1988. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J. Clin. Investig. 82:1560-1566.
51. Salas, F., J. Fichmann, G. K. Lee, M. D. Scott, and P. J. Rosenthal. 1995. Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect. Immun. 63:2120-2125.
52. Sijwali, P. S., K. Kato, K. B. Seydel, J. Gut, J. Lehman, M. Klemba, D. E. Goldberg, L. H. Miller, and P. J. Rosenthal. 2004. Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc. Natl. Acad. Sci. USA 101:8721-8726.
53. Sijwali, P. S., J. Koo, N. Singh, and P. J. Rosenthal. 2006. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol. Biochem. Parasitol. 150:96-106.
54. Sijwali, P. S., and P. J. Rosenthal. 2004. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 101:4384-4389.
55. Sijwali, P. S., B. R. Shenai, J. Gut, A. Singh, and P. J. Rosenthal. 2001. Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem. J. 360:481-489.
56. Silva, A. M., A. Y. Lee, J. W. Erickson, and D. E. Goldberg. 1998. Structural analysis of plasmepsin II. A comparison with human aspartic proteases. Adv. Exp. Med. Biol. 436:363-373.
57. Silva, A. M., A. Y. Lee, S. V. Gulnik, P. Maier, J. Collins, T. N. Bhat, P. J. Collins, R. E. Cachau, K. E. Luker, I. Y. Gluzman, S. E. Francis, A. Oksman, D. E. Goldberg, and J. W. Erickson. 1996. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 93:10034-10039.
58. Stead, A. M., P. G. Bray, I. G. Edwards, H. P. DeKoning, B. C. Elford, P. A. Stocks, and S. A. Ward. 2001. Diamidine compounds: selective uptake and targeting in Plasmodium falciparum. Mol. Pharmacol. 59:1298-1306.
59. Tucker, T. J., W. C. Lumma, Jr., L. S. Payne, J. M. Wai, S. J. de Solms, E. A. Giuliani, P. L. Darke, J. C. Heimbach, J. A. Zugay, W. A. Schleif, J. C. Quintero, E. A. Emini, J. R. Huff, and P. S. Anderson. 1992. A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity. J. Med. Chem. 35:2525-2533.
60. World Health Organization. 2003. Africa malaria report. World Health Organization, Geneva, Switzerland.